• Users Online: 257
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 2  |  Issue : 1  |  Page : 42-46

Efficacy and safety of infliximab on colonic mucosal healing in patients with moderate-to-severe ulcerative colitis


1 Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut; Gastroenterology Unit, Farwaniya Hospital, Kuwait City, Kuwait
2 Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt; Gastroenterology Unit, Farwaniya Hospital, Kuwait City, Kuwait
3 Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut, Egypt

Correspondence Address:
Elham A Hassan
Department of Tropical Medicine and Gastroenterology, Assiut University Hospital, Assiut
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JCMRP.JCMRP_31_16

Rights and Permissions

Background Infliximab (IFX), a monoclonal anti-tumor necrosis factor-α antibody, is commonly used for the treatment of moderate-to-severe inflammatory bowel diseases. No sufficient data are present for its role in the treatment of ulcerative colitis (UC) in our area. We studied the efficacy and safety profile of IFX in treating patients with refractory UC. Patients and methods This prospective study included 48 adult patients with refractory UC. They received IFX (5 mg/kg) intravenously at weeks 0, 2, and 6 at Farwaniya Hospital, Kuwait, between 2013 and 2016. Patients were followed-up for 12 weeks and re-evaluated for clinical and endoscopic response to therapy. Results With the exception of four patients who were excluded from the study because of serious side-effects, 44 patients completed the study. At week 12, clinical remission and colonic mucosal healing were achieved in 29 (65.9%) patients after initiating IFX treatment. Of these 29 responders, no relapse occurred. No serious adverse events or mortalities were recorded during the course of treatment among the studied patients treated with IFX. Conclusion IFX is a safe and efficient therapy that may be useful for induction of remission in patients with refractory UC.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed70    
    Printed1    
    Emailed0    
    PDF Downloaded17    
    Comments [Add]    

Recommend this journal